MAManahito Aoki

Manahito Aoki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Manahito Aoki has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Discoloration and chemical stability of entacapone in concomitant simple suspensions with magnesium oxide

    by Manahito Aoki, Ginjiro Kato, Kazuki Akira, Mitsuhiro Sugawara

    Background: In clinical practice, entacapone and magnesium oxide (MgO) tablets are administered via enteral tubes using a simple suspension method. Simple co-suspensions of entacapone and MgO gradually turned deep red. However, there is still no report about the cause of the discoloration. In this study, the chemical stability of entacapone in co-suspension with MgO was investigated, and the cause of discoloration was elucidated. Passability of the drug through the feeding tube was also evaluated. Methods: An entacapone tablet was suspended, with or without an MgO tablet using a simple suspension method. The supernatants of the suspensions were analyzed using high-performance liquid chromatography to examine the chemical stability of entacapone and the passage of the drug through an enteral tube. The supernatants were analyzed using ultraviolet-visible spectrophotometry. Aqueous solutions of entacapone were prepared at various pH values and analyzed using ultraviolet-visible spectrophotometry and 1 H nuclear magnetic resonance spectroscopy. Results: High-performance liquid chromatography of simple suspensions with or without MgO showed only one entacapone peak, and the recovery of entacapone from the suspensions was quantitative, even after passing through an enteral tube. Using aqueous solutions of authentic entacapone, the colors and the ultraviolet-visible spectra were found to be dependent on the pH values. Conclusions: Entacapone is stable in simple suspensions with or without MgO, and the cause of discoloration by the co-suspension is plausibly not the degradation of entacapone, but the pH-dependent formation of the divalent anion. Discoloration of the co-suspensions has no effect on the dose in tube administration.

  • Two Cases at Community Pharmacies of Mercaptopurine Removal from a Disk-type Powder-packaging Machine by Wiping It with Water

    by Wakana Yoshida, Sakae Saito, Magoichi Sako, Masamitsu Noda, Satoru Kawaguchi, Kazuya Arai, Saori Anzai, Satoshi Kubota, Kiyoshi Shibuya, Mitsuru Machida, et al.

    “Leukerin® powder 10%” containing mercaptopurine (6-MP) is an oral anticancer drug that requires careful handling. As a powder formulation, there are risks of exposure due to scattering during dispensing and possible 6-MP contamination to other drugs due to adhesion to the packaging machine. We previously reported that wiping with an alcohol-containing towel is useful for removing scattered powder after dispensing. However, it is recommended to wipe disk-type powder-packaging machines with water instead of cleaning with the alcohol-containing towel. Hence, we scattered 6-MP powder 100 mg (total amount of 6-MP: 10 mg), and then wiped with water three times using different types of cloth each time. We confirmed that third time wiping cloth did not have any 6-MP. Furthermore, we confirmed that the adhering 6-MP could be removed by wipe-cleaning (water-wiping twice and dry-wiping once) after dispensing 6-MP powder at two pharmacies that routinely dispensed 6-MP powder using a disk-type powder-packaging machine. In addition, we confirmed the adhesion of 6-MP in parts of the machine not cleaned by wipe-cleaning and also in parts that were washed only with water, in both the pharmacies. Based on the above observations, we recommend the following steps for cleaning disk-type powder-packaging machines after dispensing 6-MP powder: (1) wipe-cleaning that includes water-wiping twice and then dry-wiping once, (2) cleaning all areas of the packaging machine, and (3) wipe-cleaning with water before washing with water.

  • Open Access

    Mixture of clopidogrel bisulfate and magnesium oxide tablets reduces clopidogrel dose administered through a feeding tube

    by Manahito Aoki, Midori Naya, Shiho Arima, Kaori Shinohara, Masahiro Kato, Kiyoshi Shibuya, Masaki Ohtawa, Tohru Nagamitsu, Katsuya Otori

    Background: In clinical practice, a mixed suspension of clopidogrel bisulfate and magnesium oxide (MgO) tablets is administered frequently via a feeding tube. However, there is no report on the changes occurring when suspensions of these two drugs are combined, including the effects or potential decrease in dose following tube administration. Thus, the purpose of our study was to investigate the (i) changes caused by mixing clopidogrel bisulfate (ion form) and MgO tablets and (ii) effects on the administered clopidogrel dose after passing through a feeding tube. Methods: The molecular structure of clopidogrel generated in a mixture of clopidogrel bisulfate and a basic compound, such as sodium bicarbonate or MgO tablet, was determined by 1H-NMR after extraction and purification. The suspension of clopidogrel bisulfate tablet alone and the mixed suspension of clopidogrel bisulfate tablet and MgO tablet were passed through a feeding tube. We compared the yield of the molecular form of clopidogrel from each passed fraction. Results: The substance obtained from the mixture of clopidogrel bisulfate tablet and sodium bicarbonate or MgO tablet was identified as the molecular form of clopidogrel, and chemical degradation did not occur under these conditions. In the tube passage test, the yield of clopidogrel (molecular form) from the mixture of clopidogrel bisulfate and MgO tablets was lower than that from the suspension of clopidogrel bisulfate tablet alone. Conclusions: The mixture of clopidogrel bisulfate and MgO tablets caused a considerable reduction in the administered dose passed through the feeding tube. Therefore, it is recommended to administer the suspensions of clopidogrel bisulfate and MgO tablets separately for safe and effective pharmacotherapy.


  • Open Access

    Safe Handling Method for Splitting Azathioprine Tablets

    by Manahito Aoki, Satsuki Oda, Satoshi Kubota, Sakae Saito, Norio Yokota, Atsushi Shibazaki, Kiyoshi Shibuya, Magoichi Sako, Katsuya Otori

    The immunosuppressant azathioprine (AZA) is classified as a hazardous drug. AZA contamination during tablet-splitting increases exposure risk. However, there is no study on contamination and exposure during AZA tablet splitting and dispensing. AZA tablet splitting and dispensing methods were classified based on whether tweezers are used during splitting and packaging. In Dispensing Method (1), no tweezers were used in either step. In Dispensing Method (2), no tweezers were used during tablet splitting, but were used during packaging. In Dispensing Method (3), tweezers were used in both steps. After AZA half-tablet split-dispensing, we quantified the adherent AZA removed from the tools, packaging machines, and dispensing counters by three consecutive wipings with water-dampened polypropylene cloths. A large amount of AZA adhered to the gloves used in Dispensing Methods (1) and (2), wherein tablets were placed with gloved hands, compared with Dispensing Method (3), wherein tablets were held with tweezers. Thus, the gloves must be replaced before touching the packaging paper during the final step. After three consecutive wipings, AZA was not detected at most of the sites in the third round. Thus, we recommend that (1) AZA tablet splitting should be performed while wearing gloves, (2) the gloves should be changed before packaging the half tablets, and (3) the tools, packaging machines, and dispensing counters should be wiped twice or thrice with a water-dampened cloth after dispensing.


  • Evaluation of Measures against Exposure during Administration of Hazardous Drugs through a Feeding Tube

    by Manahito Aoki, Yumi Hamasaki, Midori Naya, Hiroki Shishikura, Masahiro Kato, Kiyoshi Shibuya, Meiko Aoyagi, Katsuya Otori

    Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies


  • Open Access

    Clinical Pharmacy Education in Japan: Using Simulated Patients in Laboratory-Based Communication-Skills Training before Clinical Practice

    by Rie Kubota, Kiyoshi Shibuya, Yoichi Tanaka, Manahito Aoki, Megumi Shiomi, Wataru Ando, Katsuya Otori, Takako Komiyama

    The Japanese pharmaceutical curriculum was extended from four to six years in 2006. Students now receive practical communication-skills training in their fourth year, before progressing to train in hospital and community pharmacies in their fifth year. Kitasato University School of Pharmacy, Tokyo, had established a program to meet these aims before the 2006 guidance. In the present study, we discuss and evaluate the features of this communication-skills training program. This study enrolled 242 fourth-year pharmacy students at Kitasato University. Students filled out a questionnaire survey after completing the laboratory element of their undergraduate education. As part of training, students were asked to obtain patient data from a model medical chart, before performing simulated patient interviews covering hospital admission and patient counseling. These simulations were repeated in a small group, and feedback was provided to students by both the simulated patient and the faculty after each presentation. It was found that students were able to develop their communication skills through this approach. Thus, an effective system of gradual and continuous training has been developed, which allows students to acquire clinical and practical communication skills.